Carotid artery stenting (CAS) is increasingly offered to patients with carotid artery stenosis. Although CAS is a less invasive (and thus more attractive) alternative compared with carotid endarterectomy, it requires the use of contrast material. A possible side effect from the use of contrast material during CAS is the development of contrast-induced acute kidney injury (CI-AKI). This review discusses the incidence/prevalence and clinical significance of CI-AKI developing after CAS. We also discuss possible measures to reduce the incidence of CI-AKI after CAS.
KernanWNOvbiageleBBlackHR; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160–2236.
2.
European Stroke Organisation, TenderaMAboyansVBartelinkML; ESC Committee for Practice Guidelines. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the task force on the diagnosis and treatment of peripheral artery diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(22):2851–2906.
3.
RicottaJJAburahmaAArcherEEskandariMFariesPLalBK; Society for Vascular Surgery. Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease: executive summary. J Vasc Surg. 2011;54(3):e1–e31.
4.
YagantiVAlaniFYagantiSGoldbergSMcCormickD. Use of gadolinium for carotid artery angiography and stenting in patients with renal insufficiency. J Ren Care. 2009;35(4):211–218.
5.
KatoTSakaiHTsujimotoMNishimuraY. Prolonged carotid sinus reflex is a risk factor for contrast-induced nephropathy following carotid artery stenting. AJNR Am J Neuroradiol. 2011;32(3):441–445.
6.
SchneiderLMRoubinGS. Minimal contrast use in carotid stenting: avoiding contrast pitfalls. J Invasive Cardiol. 2007;19(1):37–38.
7.
DonahueMViscontiGFocaccioA. Acute kidney injury in patients with chronic kidney disease undergoing internal carotid artery stent implantation. JACC Cardiovasc Interv. 2015;8(11):1506–1514.
FuMDaiWYeYLuQHeW. High dose of atorvastatin for the treatment of contrast-induced nephropathy after carotid artery stenting [published online December 29, 2015]. Am J Ther. 2015.
10.
BarrettBJParfreyPS. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med. 2006;354(4):379–386.
11.
McCulloughPAAdamABeckerCR; CIN Consensus Working Panel. Risk prediction of contrast-induced nephropathy. Am J Cardiol. 2006;98(6A):27K–36K.
12.
McCulloughPAStaculFBeckerCR; CIN Consensus Working Panel. Contrast-induced nephropathy (CIN) Consensus working panel: executive summary. Rev Cardiovasc Med. 2006;7(4):177–197.
13.
TsaiTTPatelUDChangTI. Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry. JACC Cardiovasc Interv. 2014;7(1):1–9.
14.
DavidsonCStaculFMcCulloughPA; CIN Consensus Working Party. Contrast medium use. Am J Cardiol. 2006;98(6A):42K–58K.
15.
TuranBErkolAGulMFindikciogluUErdenI. Effect of contrast-induced nephropathy on the long-term outcome of patients with non-ST segment elevation myocardial infarction. Cardiorenal Med. 2015;5(2):116–124.
16.
AurelioADuranteA. Contrast-induced nephropathy in percutaneous coronary interventions: pathogenesis, risk factors, outcome, prevention and treatment. Cardiology. 2014;128(1):62–72.
17.
StaculFAdamABeckerCR; CIN Consensus Working Panel. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol. 2006;98(6A):59K–77K.
18.
PappyRStavrakisSHennebryTAAbu-FadeiMS. Effect of statin therapy on contrast-induced nephropathy after coronary angiography: a meta-analysis. Int J Cardiol. 2011;151(3):348–353.
19.
ParaskevasKIGiannoukasADKotsikorisIMikhailidisDP. Contrast-induced nephropathy and the vascular patient. Angiology. 2010;61(8):721–723.
20.
AthyrosVGTziomalosKFlorentinMKaragiannisAMikhailidisDP. Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndrome: a new pleiotropic effect?Curr Med Res Opin. 2010;26(4):839–842.
21.
BriguoriCViscontiGFocaccioA; REMEDIAL II Investigators. Renal Insufficiency After Contrast Medial Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury. Circulation. 2011;124(11):1260–1269.
22.
PrinceMRArnoldusCFrisoliJK. Nephrotoxicity of high-dose gadolinium compared with iodinated contrast. J Magn Reson Imaging. 1996;6(1):162–166.
23.
SchenkerMPSolomonJARobertsDA. Gadolinium arteriography complicated by acute pancreatitis and acute renal failure. J Vasc Interv Radiol. 2001;12(3):393.
24.
SpinosaDJMatsumotoAHAngleJF. Safety of CO(2)- and gadodiamide-enhanced angiography for the evaluation and percutaneous treatment of renal artery stenosis in patients with chronic renal insufficiency. AJR Am J Roentgenol. 2001;176(5):1305–1311.
25.
GemeryJIdelsonBReidS. Acute renal failure after arteriography with a gadolinium-based contrast agent. AJR Am J Roentgenol. 1998;171(5):1277–1278.
26.
SamAD2ndMoraschMDCollinsJ. Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg. 2003;38(2):313–318.
27.
BriguoriCColomboAAiroldiF. Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures. Catheter Cardiovasc Interv. 2006;67(2):175–180.
28.
ThomsenHSAlmenTMorcosSK; Contrast Media Safety Committee Of The European Society Of Urogenital Radiology (ESUR). Gadolinium-containing contrast media for radiographic examinations: a position paper. Eur Radiol. 2002;12(10):2600–2605.
29.
SchreierDZWeaverFAFrankhouseJ. A prospective study of carbon dioxide-digital subtraction vs standard contrast arteriography in the evaluation of the renal arteries. Arch Surg. 1996;131(5):503–507.
30.
DewaldCLJensenCCParkYH. Vena cavography with CO(2) versus iodinated contrast material for inferior vena cava filter placement: a prospective evaluation. Radiology. 2000;216(3):752–757.
31.
CaridiJGStavropoulosSWHawkinsIFJr. CO2 digital subtraction angiography for renal artery angioplasty in high-risk patients. AJR Am J Roentgenol. 1999;173(6):1551–1556.
32.
DowlingKKanHSiskinG. Safety of limited supplemental iodinated contrast administration in azotemic patients undergoing CO2 angiography. J Endovasc Ther. 2003;10(2):312–316.
33.
GoldenbergIMatetzkyS. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ. 2005;172(11):1461–1471.
34.
AttallahNYassineLMusialJYeeJFisherK. The potential role of statins in contrast nephropathy. Clin Nephrol. 2004;62(4):273–278.
35.
KatsikiNAthyrosVGKaragiannisAMikhailidisDP. Contrast-induced nephropathy: an “all or none” phenomenon?Angiology. 2015;66(6):508–513.
36.
AkyuzSYaylakBAltaySKasikciogluHCamN. The role of statins in preventing contrast-induced acute kidney injury: a narrative review. Angiology. 2015;66(8):701–707.
37.
MikhailidisDPAthyrosVG. Acute kidney injury: short-term statin therapy for prevention of contrast-induced AKI. Nat Rev Nephrol. 2014;10(1):8–9.
38.
AthyrosVGKatsikiNKaragiannisAMikhailidisDP. Short-, mid-, and long-term benefits of peri-procedural high-intensity statin administration in patients undergoing percutaneous coronary intervention. Curr Med Res Opin. 2015;31(2):191–195.
39.
AthyrosVGKatsikiNKaragiannisAMikhailidisDP. Statins can improve proteinuria and glomerular filtration rate in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?Expert Opin Pharmacother. 2015;16(10):1449–1461.
40.
ZhangBCLiWMXuYW. High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis. Can J Cardiol. 2011;27(6):851–858.
41.
ParaskevasKIAthyrosVGBrianaDD. Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures. Curr Drug Targets. 2007;8(8):942–951.
42.
ParaskevasKIGiannoukasADMikhailidisDP. Statins and contrast-induced nephropathy: issues requiring further investigation. Int J Cardiol. 2011;151(3):364.
43.
AbuRahmaAFHayesJDDeelJT. Complications of diagnostic carotid/cerebral arteriography when performed by a vascular surgeon. Vasc Endovascular Surg. 2006;40(3):189–195.
44.
LiQZhaoYGWangZJiangHPLiuWBCaoBF. Effects of first high-dose atorvastatin loading in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention [published online February 23, 2016.]. Am J Ther.
45.
BroshDAssaliAVaknin-AssaH. The ACIST power injection system reduces the amount of contrast media delivered to the patient, as well as fluoroscopy time, during diagnostic and interventional cardiac procedures. Int J Cardiovasc Intervent. 2005;7(4):183–187.
46.
ParlaniGDe RangoPVerziniF. Safety of carotid stenting (CAS) is based on institutional training more than individual experience in large-volume centres. Eur J Vasc Endovasc Surg. 2013;45(5):424–430.
47.
ModrallJGChungJKirkwoodML. Low rates of complications for carotid artery stenting are associated with a high clinician volume of carotid artery stenting and aortic endografting but not with a high volume of percutaneous coronary interventions. J Vasc Surg. 2014;60(1):70–76.
